title: Detection of circulating heparin in cancer patients after port flush of indwelling venous access devices:  implications for bevacizumab-associated thrombosis.
authors.forename: Ali
authors.initials: A
authors.lastname: Amirkhosravi
authors.forename: Todd
authors.initials: T
authors.lastname: Meyer
authors.forename: Meghan
authors.initials: M
authors.lastname: Hatfield
authors.forename: Hina
authors.initials: H
authors.lastname: Desai
authors.forename: Mildred
authors.initials: M
authors.lastname: Amaya
authors.forename: Alane
authors.initials: A
authors.lastname: Drexler
authors.forename: Eduardo
authors.initials: E
authors.lastname: Reyes
authors.forename: John
authors.initials: J
authors.lastname: Barranco
authors.forename: Kristin
authors.initials: K
authors.lastname: Rathmann
authors.forename: Glenn
authors.initials: G
authors.lastname: Bigsby
authors.forename: John L
authors.initials: JL
authors.lastname: Francis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D002405:Catheterization, Central Venous; D002408:Catheters, Indwelling / Q000009:adverse effects*; D006493:Heparin / Q000097:blood*; D006801:Humans; D009369:Neoplasms / Q000097:blood*; D013927:Thrombosis / Q000097:blood* / Q000139:chemically induced*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006493:Heparin